We are live on
!
Find out more
GX
Greylock XII Portfolio holdings
AUM
$51.9M
1-Year Est. Return
11.52%
This Fund
S&P 500
This Quarter
Est. Return
-28.48%
1 Year Est. Return
-11.52%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$15.2M
AUM Growth
-$6.49M
(-30%)
Cap. Flow
-$441K
Cap. Flow
% of AUM
-2.91%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Larimar Therapeutics
LRMR
|
+$441K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 100% |
| 2 | Healthcare | 0% |
Similar funds
KIA
FCM
OPPM
SAM
ACP
ZIM
SCPM
PGA
Greylock XII's Q1 2016 Portfolio in Review
As of Q1 2016, Greylock XII held 2 positions worth $15.2M, down 30% from $21.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Greylock XII's Q1 2016 filing shows 1 closed position. The largest sale was Larimar Therapeutics, an estimated $441K.
By sector, the portfolio is most concentrated in Communication Services at 100% of assets, up from 98% a quarter earlier, followed by Healthcare.
- Greylock XII fully exited Larimar Therapeutics in Q1 2016, selling an estimated $441K.
- Greylock XII's ten largest holdings make up 100% of its $15.2M portfolio in Q1 2016.
- Greylock XII opened 0 new positions and closed 1 in Q1 2016.
- Greylock XII's portfolio value fell 30% quarter-over-quarter to $15.2M.
Based on Greylock XII's 13F filing for Q1 2016, filed 22 Apr 2016.